

Pharmacokinetic and biochemical profiling of Sodium Dichloroacetate in pregnant ewes and fetuses

Serene Joseph*, Abhisheak Sharma*, Lloyd.P. Horne, Charles E. Wood, Taimour
Langaee, Margaret O. James, Peter W. Stacpoole, and Maureen Keller-Wood

Department of Pharmacodynamics (S.J., M. K.-W.), Department of Pharmaceutics
(A.S.), Department of Medicinal Chemistry (M.O.J.), Department of Pharmacotherapy
and Translational Research (T.L.), Center for Pharmacogenomics and Precision
Medicine (T.L.), and Departments of Medicine and Biochemistry and Molecular Biology
(L.H., P.W.S.), Department of Physiology and Functional Genomics (C.E.W), University
of Florida, Gainesville, Florida 32610, USA

Running title:

Pharmacokinetic and biochemical profiling of DCA

Address correspondence to:

Dr. Serene Joseph Ph.D., Department of Pharmacodynamics, University of Florida,

1345 Center Drive, P.O. Box 100485, Gainesville, FL 32610-0485., E-mail

serenejoseph@ufl.edu

*Both authors contributed equally

Number of text pages: 28

Number of tables: 1

Number of figures: 6

Number of references: 39

Number of words in the Abstract: 192

Number of words in Introduction: 696

Number of words in Discussion: 1219

Abbreviations: DCA, dichloroacetate; PDK4- Pyruvate dehydrogenase kinase 4; PDC, pyruvate dehydrogenase complex; GSTZ1, glutathione transferase zeta1; TCA, tricarboxylic acid; PDK, pyruvate dehydrogenase kinase; CL, clearance; V_d , volume of distribution; GC-MS- Gas chromatography- mass spectrometry; BF_3 - boron trifluoride; rpm- revolutions per minute; MM- Michaelis-Menten

Abstract

Sodium dichloroacetate (DCA) is an investigational drug that shows promise in the treatment of acquired and congenital mitochondrial diseases, including myocardial ischemia and failure. DCA increases glucose utilization and decreases lactate production, and so may also have clinical utility in reducing lactic acidosis during labor. In the current study we test the ability of DCA to cross the placenta and be measured in fetal blood following intravenous administration to pregnant ewes during late gestation and labor. Sustained administration of DCA to the mother over 72h achieved pharmacologically active levels of DCA in the fetus and decreased fetal plasma lactate concentrations. Multi-compartmental pharmacokinetics modeling indicated drug metabolism in the fetal and maternal compartments is best described by the DCA inhibiting lactate production in both compartments, consistent with our finding that the hepatic expression of the DCA-metabolizing enzyme GSTZ1 was decreased in the ewes and their fetuses exposed to the drug. We provide the first evidence that DCA can cross the placental compartment to enter the fetal circulation, inhibit its own hepatic metabolism in the fetus, leading to increased DCA concentrations and decreased fetal plasma lactate concentrations during its parenteral administration to the mother.

Significance statement

This study was the first to administer sodium dichloroacetate (DCA) to pregnant animals (sheep). It showed that DCA administered to the mother can cross the placental barrier and achieve concentrations in fetus sufficient to decrease fetal lactate concentrations. Consistent with findings reported in other species, DCA-mediated

inhibition of GSTZ1 was also observed in ewes, resulting in reduced metabolism of DCA after prolonged administration.

Introduction

Defects in mitochondrial function have been associated with cardiomyopathies and disorders of skeletal muscle (Eriksson et al., 2003; Magida and Leinwand, 2014; Fatica et al., 2019). We previously found that sheep fetuses exposed to hypercortisolemia in late pregnancy suffered an increased rate of stillbirth and perinatal mortality (Keller-Wood et al., 2014); this effect of a chronic increase in cortisol is similar to the observation that the risk of late gestation stillbirth is increased in human pregnancies complicated by chronic maternal hypercortisolemia secondary to maternal stress (László et al., 2013; Silver and Ruiz, 2013) or by maternal Cushing's syndrome (Brue et al., 2018). Transcriptomic and metabolic analyses of heart and skeletal muscle from the fetuses and newborns from our ovine model of gestational hypercortisolemia suggested that inhibition of mitochondrial metabolism (Richards et al., 2014; Walejko et al., 2019; Joseph et al., 2020) may be a predisposing factor in the development of bradycardia and altered ECG patterns at the time of delivery (Antolic et al., 2018). Excess cortisol exposure in utero is associated with overexpression of *PDK4*, encoding the predominant pyruvate dehydrogenase kinase isoform in cardiac and skeletal muscle (Pilegaard and Neufer, 2004). PDK inhibits the mitochondrial pyruvate dehydrogenase complex (PDC) which catalyzes the rate-determining step in the oxidation of glucose-derived pyruvate to acetyl CoA, thereby linking cytoplasmic glycolysis to the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (Stacpoole, 2017). Four isoforms of pyruvate dehydrogenase kinase (PDK 1-4) phosphorylate and inhibit PDC, while two pyruvate dehydrogenase phosphatases (PDP 1 and 2) dephosphorylate the complex and restore catalytic activity (Sugden and Holness, 2003). Inhibition of PDC

activity decreases the utilization of pyruvate and molecules, such as lactate, in equilibrium with pyruvate.

The prototypic PDK inhibitor, dichloroacetate (DCA), has been used for many years as an investigational drug in the treatment of diverse congenital and acquired causes of PDC deficiency associated with mitochondrial energy failure. DCA has been shown to have therapeutic efficacy in neonates, improving right ventricular carbohydrate utilization and function in neonatal piglets after pulmonary artery banding (Kajimoto et al., 2019) and reducing brain injury in neonatal mice after hypoxic ischemia (Sun et al., 2016). DCA was reported to be effective in treating a human newborn with lactic acidosis due to inherited mitochondrial disease (Bennett et al, 2020). Therefore, we hypothesized that DCA, administered intravenously (IV) to pregnant ewes, would cross the placenta, and provide a therapy for treatment of lactic acidosis and mitochondrial dysfunction during labor and delivery. Our long-term goal is to determine if DCA can improve myocardial bioenergetics and thus mitigate or prevent fetal bradycardia and distress during labor in cortisol-exposed fetuses. The present studies tested the hypothesis that DCA can cross the placenta to the fetal circulation when administered to pregnant ewes and achieve pharmacologically active concentrations in the ovine fetus.

Effective therapy with DCA is dependent on DCA concentrations, which is limited by rapid metabolism of DCA to the inactive metabolite, glyoxylate, by the enzyme glutathione transferase zeta1 (GSTZ1) (Cornett et al., 1999). The enzyme is predominantly expressed in liver cytoplasm and mitochondria, although other tissues express much lower protein levels (James et al., 2017; Squirewell et al., 2020). Repeated doses of DCA can suppress the expression of GSTZ1, thereby decreasing

the rate of DCA metabolism (Cornett et al., 1999). DCA metabolism by GSTZ1 is influenced by GSTZ1 haplotype in humans (Shroads et al., 2012; James et al., 2017), and also by age (Shroads et al., 2008) and liver chloride concentration (Jahn et al., 2018). The predicted ovine sequence is 84.0% similar to the human sequence (NM_145870: Homo sapiens glutathione S-transferase 1) and 79.3 % similar to the rat sequence (NM_001109445.1) of GSTZ1. The ovine GSTZ1 sequence is homologous to the EGT haplotype of the human “fast” metabolizers (Shroads et al., 2012; Shroads et al., 2015), predicting that sheep are rapid DCA metabolizers. However, in human fetal tissue, activity of GSTZ1 is very low (Li et al., 2012, Zhong et al., 2018), suggesting that the fetus might have little, if any, capacity for DCA metabolism. The present studies therefore modeled DCA pharmacokinetics to address the change in drug metabolism with repeated administration over time in the both the pregnant ewe and ovine fetus.

Methods

The pregnant sheep is a commonly used model of human pregnancy, as many aspects of ovine fetal development mirror those in humans (Barry and Anthony, 2008; Morrison et al., 2018). In addition, the model allows for placement of catheters for simultaneous blood sampling of both mother and fetus (Barry and Anthony, 2008). Two groups of animals were studied: in Study I ewes were treated with DCA as boluses every 12h for a total of 5 injections; in Study II, ewes were treated with a bolus followed by infusion of DCA. Adult, time-dated pregnant Dorset- cross ewes were used in both Studies I and II. Ewes used in Study I (n=4) were obtained from the University of Florida Animal Sciences Department, and ewes in Study II (n=10) were obtained from

Advanced Ovine Solutions (Attica, NY). Throughout the duration of the study, animals were housed in a facility with a light (12 light- 12 dark cycle) and temperature-controlled room. Ewes were maintained on a diet of pelleted feed and were supplemented with limited hay. The University of Florida Institutional Animal Care and Use Committee (IACUC) approved all animal use.

Animal Surgery

Surgery was performed on animals in late gestation under isoflurane anesthesia (Study I: 131 ± 1 -day gestation, $n=4$; Study II: 126 ± 1 -day gestation, $n=10$; term in these sheep is 146-148 days gestation). Catheters were placed ipsilaterally in a maternal femoral artery and vein and in the fetal tibial artery (Jensen et al., 2002). The catheters were exteriorized through an exit site on the flank. The animals were administered flunixin meglumine during surgery (dose, i.v) and meloxicam (dose, p.o.) postoperatively. Post-surgical care also included monitoring rectal temperatures and treatment with ampicillin (Polyflex, Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO), i.m, for 5 days and daily cleaning of the catheter exit site with povidone-iodine tincture.

Experimental Details

Study I: The pharmacokinetics study of DCA (TCI America, Portland) was performed in late gestation at least 5 days after surgery. The drug was dissolved in sterile isotonic 0.9% NaCl solution. Each dose was administered over 5 minutes to ewes in 5 doses of 25 mg/kg every 12 hours. This dose was chosen based on the

effective dosing regime in studies in adult humans with primary mitochondrial disease (James et al., 2017), and assuming that there would be distribution of DCA based on combined fetal and maternal body weight. Following the first and fifth doses (at 0 and 48h), maternal and fetal blood samples (~2 ml) were collected at -5, 0, 5, 10, 15, 20, 30, 60, 120, 240, 360, 480 and 720 minutes. Samples were placed immediately on ice before centrifuging to separate plasma, which was stored at -80°C until assayed.

Study II: DCA was administered to the ewe over a 24h period during labor, which was induced by infusions of oxytocin (4.1 mU/kg oxytocin infused over 5 min each 30 min) (Shinozuka et al., 1999). Oxytocin treatment began 48h prior to the administration of DCA. Because of the low plasma concentrations in the fetus in Study I with maternal injection at 12h intervals, but the observed decrease in metabolism with repeated injections of DCA, the dosing regime was altered for the subsequent study. In Study II the drug was administered as a bolus followed by infusions of decreasing rates over the next 24h. The first dose of DCA was administered to the ewe as an intravenous infusion of 25 mg/kg over 3 minutes; this was followed by an infusion of 12.5mg DCA/kg/h for 8 hours, and an infusion of 6.25 mg DCA/kg/h for the following 16 hours. This cohort of animals included ewes that either had been treated with cortisol (1 mg/kg/d) starting on day 115 of pregnancy or that received no DCA. Two animals treated with DCA delivered either before or immediately following the last sample at 24h of DCA. These samples were not included in the analysis of DCA concentrations or of plasma glucose and lactate. Plasma was collected for measurement of glucose and lactate during the periods of DCA treatment and an aliquot was stored at -80°C until for analysis of DCA concentrations by gas chromatography-mass spectrometry (Yan et al., 1997).

Determination of DCA Concentration in the Plasma

The DCA levels in the blood samples were measured after derivatization and extraction, as previously described (Yan et al., 1997). Plasma samples (200 μ l) and an internal standard of 2-ketohexanoic acid (10 μ g) were mixed with 500 μ l of BF_3 -methanol complex in a glass tube and heated for 15 min at 110 $^{\circ}\text{C}$. Upon cooling, 1 ml of methylene chloride and 1ml of water were added to the reaction mixture, then vortexed for 5 min and allowed to stand for 10 minutes. After centrifugation at 3000 rpm, the methylene chloride layer was transferred to a glass vial for GC-MS analysis.

Pharmacokinetic Modelling of DCA in Maternal and Fetal Plasma

Plasma concentration-time values of DCA in both ewes and fetuses in Study I were subjected to non-compartmental and multi-compartmental analyses (Phoenix 64; Certara USA, Inc.). Non-compartmental analysis on day 1 and day 3 concentration-time data was performed separately for ewes and fetuses, both to understand the extent of accumulation and to develop a combined pharmacokinetics model of DCA in mother and fetus. The area under the curve (AUC) for ewes and the fetuses were calculated separately using the linear trapezoidal method for day 1 and day 3. Clearance (CL) and volume of distribution (V_d) were calculated for both day 1 and day 3 for ewes (Phoenix WinNonlin version 7.1).

Plasma concentration-time data for both ewes and fetuses were further subjected to multicompartmental modeling (Phoenix NLME version 7.1). Population pharmacokinetics models with two or three disposition compartments, first order,

Michaelis-Menten (MM), parallel first-order, parallel MM or parallel first-order, parallel, and MM elimination were evaluated to best describe the concentration-time data. Residual error was described by a combined error (proportional and additive) model. A semi-mechanistic multi-compartmental model describing the auto-inhibition of DCA was developed to obtain the best fit for concentration-time data of both mothers and fetuses. The model included an inter-compartment between the mother (A_1) and fetus (A_3), which physiologically could be considered the placental compartment (A_2). In order to describe the decreased clearance and increased exposure of DCA from day 1 to day 3, a model describing potential autoinhibition (INH_M and INH_F) of clearances of both ewes (CL) and fetuses (CL_F) was implemented as described in Equations 1-5 (Bulitta et al., 2013).

$$dA_1/dt = - ((1-INH_M) * CL * C) - (A_1 * K_{12} - A_2 * K_{21}) \quad (1)$$

$$dINH_M/dt = K_p * ((I_{max} * C) / (IC_{50} + C)) - INH_M \quad (2)$$

$$dA_2/dt = (A_1 * K_{12} - A_2 * K_{21}) - (A_2 * K_{23} - A_3 * K_{32}) - ((1-INH_F) * CL_F * C_2) \quad (3)$$

$$dA_3/dt = (A_2 * K_{23} - A_3 * K_{32}) \quad (4)$$

$$dINH_F/dt = K_p * ((I_{max} * C_2) / (IC_{50} + C_2)) - INH_F \quad (5)$$

Here, K_p , I_{max} , and IC_{50} are turnover rate constant for inhibition, maximum inhibition, and concentration causing 50% of I_{max} , respectively. Micro constants, K_{12} , K_{21} , K_{23} , and K_{32} , are inter-compartmental distribution rate constants.

Glucose and Lactate Concentrations

Maternal and fetal glucose and lactate concentrations were measured from plasma samples collected into tubes containing potassium oxalate and sodium fluoride

(YSI Model 2700 glucose/lactate analyzer, Yellow Springs, OH.) The samples were maintained on ice prior to analysis and all readings were done in duplicate.

GSTZ1 Genotyping

We tested for haplotypes of the GSTZ1 gene in several commonly used breeds of sheep. DNA was extracted from the lung tissue of 6 sheep fetuses (2 each from Suffolk, Rambouillets and Dorset cross breeds) using the QIAamp® DNA Mini Kit (Qiagen, MD, USA) on approximately 250 mg of tissue. The concentration of DNA was determined on a nanodrop spectrophotometer (ThermoFisher, Waltham, MA, USA). Primers for PCR and sequencing were designed for the predicted GSTZ1 gene (ensemble ID: ENSOARG00000002420) using Primer 3 software, from 10 exons (**Supplemental Table 1**). Designated DNA fragments were amplified by PCR, using a HotStar Taq Master Mix kit (Qiagen) on a thermocycler. Multiple PCR conditions with different annealing temperatures and times were tried until single sharp bands with the right DNA fragment size were obtained. The PCR amplicons were verified on agarose gel. The PCR amplicons were then sequenced by Sanger sequencing and the obtained sequences were analyzed by comparing with published predicted sheep GSTZ1 sequence (Shroads et al., 2012).

Protein expression of GSTZ1

Ewes were sacrificed 24 hours after the last dose of DCA and tissues were collected. Samples of liver, 2 to 3 g, were homogenized in a volume of buffer 1 (0.25 M

sucrose, 0.05 M Tris-Cl pH 7.4, 5 mM EDTA, 1 mM DTT, 0.2 mM PMSF) equal to four times the tissue weight. The homogenates were centrifuged at 600 x g for 10 min to sediment nuclei and unbroken cells, at 13,300 x g for 20 min to sediment mitochondria and 145,000 x g for 45 min to sediment microsomes (Smeltz et al., 2019). The 145,000 x g supernatant was the cytosol fraction. The mitochondrial pellet was suspended in buffer 1 and re-sedimented at 13,300 x g for 20 min. The washed pellet was resuspended in a volume of buffer 1 equal to half the weight of tissue. The protein concentration of each subcellular fraction was determined with a bicinchoninic acid reagent (Thermo-Fisher, Waltham, MA). Liver mitochondrial and cytosolic fractions were flushed with nitrogen and stored in aliquots at -80 °C until use.

For quantification of GSTZ1 protein expression, the liver cytosol samples, 80 µg protein, as well as a single rat liver cytosol sample, 5 µg (as reference) were separated by sodium dodecyl sulfate polyacrylamide gel-electrophoresis with 12% polyacrylamide gels then electrophoretically transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). Once transferred, the membrane was allowed to block in low-fat milk for one hour, then overnight in primary antibody (custom-prepared rabbit-anti-rat GSTZ1) (Smeltz et al., 2019) at a 1:200 antibody to milk ratio. After washing, membranes were treated with horseradish peroxidase-labeled goat anti-rabbit secondary antibody, 1:5000 (GE Healthcare, Chalfont St. Giles, UK) and incubated for 1 hour. The membrane was washed, then exposed to the ECL Plus Western Blotting detection reagents (Thermo Fisher Scientific, Waltham, MA), and protein signals were quantitated on the ChemiDoc MP System (Bio-Rad Laboratories, Hercules, CA). Preliminary studies showed that polyclonal antibodies raised in rabbits to rat and human

GSTZ1 full-length protein cross-reacted with a sheep protein at the expected molecular weight of GSTZ1. The intensities of bands in the sheep liver cytosol samples were compared to the intensity of the band from the rat liver cytosol, adjusted for total protein loaded, to give relative expression levels.

Statistical Analysis

Maternal and fetal glucose and lactate values in Study I on day 1 and day 3, and values over the 24h of treatment in Study II, were analyzed by two-way analysis of variance with repeated measures across time (Sigmaplot v13.0). Between day comparisons at multiple time points were performed by post hoc tests, using the Bonferroni t-test method. In case of failed conditions of normality, a non-parametric alternative was used. Maternal lactate and fetal glucose to lactate ratios between day 1 and day 3 were analyzed by Friedman's repeated measures analysis of variance on ranks due to the failed normality test. In Study II, plasma glucose was analyzed by one-way ANOVA corrected for repeated measures; plasma lactate values were not normally distributed and were analyzed by Friedman's repeated analysis of variance on ranks. Data from fetuses that delivered before the end of the 24h sampling period were excluded, therefore samples from only 8 ewes and fetuses are included in this analysis. Differences in GSTZ1 protein expression between maternal and fetal livers and between control and DCA-treated sheep were evaluated by one-way ANOVA, with multiple comparisons.

Results

Pharmacokinetic Analysis of DCA in the Mother and Fetus

Repeated administration of DCA to the ewe increased DCA concentrations in both the ewe and the fetus. In Study I, in which DCA was administered over 3 days, an increase in trough (dosing interval) concentrations of DCA was observed in both mothers and fetuses with time (Figure 1), consistent with the inhibition of metabolism of DCA by GSTZ1 from repeated drug dosing. Accordingly, pharmacokinetics parameters derived from non-compartmental analysis of the DCA concentrations in Study I revealed marked increases in the area under the plasma DCA concentration-time curve on day 3 relative to day 1 (10.5-fold and 147-fold for ewes and fetuses, respectively). To describe the autoinhibition of the metabolism of DCA in both ewes and fetuses, and to account for ewe-to-fetus transfer of DCA, a best fit multi-compartmental pharmacokinetic model was developed (Figure 2) best described by maternal (central), placental, and fetal compartments. The best fit model was selected, based on the residual sum of squared error, Akaike's Information Criterion, visual predictive checks (VPCs -**Supplemental Figure 1**), diagnostic plots (**Figure 3, Supplemental Figure 2**) and bootstrapping. The concentration-time data were best described by the autoinhibition of mother and fetal clearances. Clearances of DCA without autoinhibition in ewes and fetuses were 195.7 ± 1.2 and 122.4 ± 28.2 L/h, respectively, suggesting lower expression of GSTZ1 in the fetus, compared to the mother (Table 1). Apparent volumes of distribution of both mother (63.3 L) and fetus (51.6 L) were greater than the total blood volume, reflecting extravascular distribution and accumulation in tissues. The maximum extent of autoinhibition was found to be 74%, with an IC_{50} of 0.04 mg/L. The developed model

accommodated the complex pharmacokinetics of DCA in both ewes and fetuses simultaneously, including the DCA mediated inhibition of GSTZ1. The DCA concentration vs time in ewes and fetuses in Study II was also consistent with this model (Figure 3).

Expression of GSTZ1 in the sheep.

The sequences obtained from the 6 animals of different strains of sheep were analyzed for single nucleotide polymorphisms (SNPs) and no SNPs were identified in the sheep *GSTZ1* gene.

Immunoblot analysis of the maternal and fetal control livers showed higher levels of expression of GSTZ1 in the untreated ewe compared to the untreated fetus. In both ewe and fetus, DCA treatment reduced the protein expression of GSTZ1 in liver cytosol (Figure 4, Supplemental figure 3). There was no difference in GSTZ1 protein expression between the DCA-treated maternal and fetal samples. GSTZ1 expression was also detected in liver mitochondrial extracts from control sheep, but expression was lower than in cytosol (data not shown). Preliminary studies examined GSTZ1 expression in kidney cytosol and mitochondria and in placental cytosol, but expression was very low in kidney and not detected in placenta, so no further studies were done with these tissues.

Effect of DCA on Plasma Glucose and Lactate Levels

Maternal glucose was significantly decreased on Day 3 compared to Day 1 ($p=0.04$) in Study I, but there was no significant time effect or interaction between day

and time (Figure 5). There was an overall significant decrease in maternal lactate levels ($p < 0.001$). There was a significant effect of day of treatment ($p = 0.03$) and time ($p = 0.005$), but no significant interaction of day and time on fetal glucose concentrations, and an overall effect of day ($p = 0.003$), time ($p = 0.02$) and an interaction of day and time ($p = 0.010$), on fetal plasma lactate concentrations. In both the ewe and the fetus, the glucose to lactate ratio was significantly increased ($p = 0.007$ and < 0.001 respectively) on day 3 as compared to day 1 (data not shown).

In Study II, the infusion of DCA significantly decreased both maternal and fetal plasma lactate concentrations ($p < 0.002$) but did not significantly change maternal or fetal plasma glucose concentrations (Figure 6).

Discussion

DCA has long been investigated for its effects on intermediary metabolism and mitochondrial bioenergetics (James et al., 2017). Phase I-III clinical trials have evaluated its therapeutic effects in patients with cancer, diabetes, hyperlipoproteinemia, cardiac and pulmonary diseases and primary mitochondrial disorders causing congenital lactic acidosis. Our study suggests that DCA can also be given in pregnancy to achieve metabolically significant effects in both mother and fetus.

One of the major limitations of transplacental therapy is the inability of drugs to cross the placental barrier and reach the fetus in effective concentrations. The DCA anion is a small, water and lipid soluble molecule with a size of 128.9 KDa, (151 KDa as the sodium salt) that can readily enter cells through convective (paracellular) absorption. In addition, the structural similarity of DCA to pyruvate and lactate enables its transport

via the pyruvate and lactate transporters, SLC16A3 (MCT4) and SLC5A8 (SMCT1). These transporters are also present in the placenta (Dimmer et al., 2000; Babu et al., 2011), providing a mechanism by which DCA crosses to the fetus.

PDC catalyzes the rate-determining step in the aerobic oxidation of glycolytically-derived pyruvate and of molecules, such as lactate and alanine, in equilibrium with pyruvate. DCA maintains PDC in the dephosphorylated and active state by inhibiting PDKs. High circulating concentrations of lactate are characteristic of fetal distress (Eguiluz et al., 1983; Smith et al., 1983) and other obstetric complications (Vannuccini et al., 2016), that, in turn, lead to decelerations in fetal heart rate. In clinical trials of severe lactic acidosis (Stacpoole et al., 1983; Stacpoole et al., 1992; Stacpoole, 1993), myocardial ischemia or failure (Bersin and Stacpoole, 1997; Michelakis et al., 2017), and pulmonary arterial hypertension (Michelakis et al., 2017), DCA reduced circulating lactate and improved cardiac efficiency, likely by shifting cardiac metabolism from fat to carbohydrate oxidation. DCA has also been similarly effective in adult rodent models of ischemia/reperfusion injury (Bersin and Stacpoole, 1997), and in hemorrhagic and septic shock (Subramani et al., 2017; McCall et al., 2018). To our knowledge, DCA has not previously been tested in a fetal model, although it has been shown to be effective in pediatric models of disease (Sun et al., 2016), and in human pediatric cases of congenital mitochondrial disease (Stacpoole et al., 2008), including in a newborn with severe lactic acidosis (Bennett et al., 2020).

Pharmacokinetic modeling of the DCA drug concentrations across time in the maternal and fetal blood suggested that it crossed the placenta and attained metabolically effective concentrations in the fetus. Sustained dosing of the drug

increased its concentration in the fetus and produced significant decreases in fetal lactate levels on day 3. Using this information, we administered DCA to the ewe as a rapid infusion, followed by a prolonged infusion to elicit sustained, pharmacodynamically effective concentrations.

DCA is a mechanism-based inhibitor of GSTZ1, resulting in reduced expression as well as reduced activity of the enzyme and decreased plasma DCA clearance upon repeat exposure. The inhibition of GSTZ1 protein expression is thought to occur secondary to protein degradation caused by formation of adducts (Anderson et al., 1999; Tzeng et al., 2000); incubation of GSTZ1 with DCA and glutathione have been shown to cause adduct formation (Cornett et al., 1999; Anderson et al., 2002). Consistent with these effects, we found that the expression of GSTZ1 was decreased in tissues in both the pregnant ewe and in fetuses receiving DCA. Moreover, our pharmacokinetic modeling of the kinetics data in the pregnant ewes and fetuses also indicates that DCA-mediated GSTZ1 inhibition occurred. Studies in humans show that the metabolism of DCA is affected by the haplotypes of the *GSTZ1* gene in the general population, dichotomizing individuals into “slow” and “fast” DCA metabolizers (Shroads et al., 2004; Shroads et al., 2012; Langae et al., 2018). The sheep sequence corresponds to the sequence in the EGT haplotype, which facilitates the most rapid metabolism of the drug in humans. Our pharmacokinetic analysis also demonstrates that the ewe rapidly metabolizes DCA. Our genotyping of the limited number of samples from various breeds of sheep failed to identify any single nucleotide polymorphisms in the gene in this species.

The doses used in this study were chosen based on the effective concentrations in adult humans and in children. In studies in adults, doses of 25 mg/kg/d have been found to be effective in primary mitochondrial disease and well-tolerated in treatment of cancer (James et al., 2017). DCA can cause a reversible sensory-motor peripheral neuropathy in chronically treated adults and, rarely, in children, who are exposed for weeks or months to the drug (Stacpoole et al., 2019). Doses of 25 mg/kg/d were not found to be toxic even in long-term studies in children with mitochondrial disease (Berendzen et al., 2006; Abdelmalak et al., 2013), despite evidence that long term treatment in adults with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) resulted in peripheral neuropathy (Stacpoole et al., 2019).

Studies on human fetal liver samples have indicated that there is no appreciable expression of GSTZ1 in the human fetus, and that GSTZ1 activity increases with postnatal age (Li et al., 2012; Zhong et al., 2018). The greater expression of GSTZ1 observed in term fetal sheep liver suggests that at full term, the ovine liver is more mature in this regard than that of human fetuses at term and leads to lower concentrations of DCA after the initial dose, which suggests that lower doses of DCA might be needed in human pregnancy. In the one report in a newborn, a dose of 30 mg/kg/d given in 2-3 divided doses was needed to prevent lactic acidosis (Bennett et al., 2020), suggesting that there is some ability to metabolize DCA in term infants. If one assumes no further clearance of the drug in the human fetus at term, then the doses used in this study would be expected to produce initial concentrations two to three-fold higher than produced in our study in fetal sheep. We would expect the concentrations

would approach the levels produced in the ovine fetus at 24h of treatment, but would be less than those produced in the mother during treatment.

A potential caveat based on our results is that lactate is a major substrate for vital fetal organs, in particular the heart; hence, excessive oxidative removal of lactate by the placental compartment and the fetal liver by activation of PDC could decrease lactate as a nutrient to the heart. We did not observe any obvious toxicity of DCA in the mother or fetus. However, future studies should determine whether in utero administration of DCA is associated with side effects in newborn lambs. Most previous studies of DCA toxicity used high doses for long periods (Donohue et al., 2003; Stacpoole, 2011). A study in pregnant rats administered 0, 14, 140 or 400 mg/kg/d on gestation days 6 to 15 showed a no-observed effect limit of 14 mg/kg/d, although much higher doses did produce cardiovascular anomalies (Smith et al., 1992).

These studies are the first to explore the pharmacological effects of DCA in pregnancy. They demonstrate that DCA can cross the placenta and achieve concentrations that significantly reduce fetal lactate concentrations in plasma. Thus, DCA might have therapeutic utility in situations of fetal distress associated with increased lactate, metabolic acidosis and cardiac distress. Future studies are required to evaluate DCA's therapeutic potential in such conditions.

Authorship contributions

Study design: Joseph, Keller-Wood, James, Langaee and Stacpoole.

Conducted experiments: Joseph, Wood, Keller-Wood, Horne, James.

Performed data analysis: Joseph, Sharma, James, Horne, and Keller-Wood.

Wrote or contributed to the writing of the manuscript: Joseph, Keller-Wood, Sharma, James, Langaee and Stacpoole.

References

- Abdelmalak M, Lew A, Ramezani R, Shroads AL, Coats BS, Langaee T, Shankar MN, Neiberger RE, Subramony SH, and Stacpoole PW (2013) Long-term safety of dichloroacetate in congenital lactic acidosis. *Mol Genet Metab* 109:139-143.
- Anderson WB, Board PG, Gargano B, and Anders MW (1999) Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids. *Chem Res Toxicol* 12:1144-1149.
- Anderson WB, Liebler DC, Board PG, and Anders MW (2002) Mass spectral characterization of dichloroacetic acid-modified human glutathione transferase zeta. *Chem Res Toxicol* 15:1387-1397.
- Antolic A, Wood CE, and Keller-Wood M (2018) Chronic maternal hypercortisolemia in late gestation alters fetal cardiac function at birth. *Am J Physiol Regul Integr Comp Physiol* 314:R342-R352.
- Babu E, Ramachandran S, CoothanKandaswamy V, Elangovan S, Prasad PD, Ganapathy V, and Thangaraju M (2011) Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. *Oncogene* 30:4026-4037.
- Barry JS and Anthony RV (2008) The pregnant sheep as a model for human pregnancy. *Theriogenology* 69:55-67.
- Bennett J, Kerr M, Greenway SC, Friederich MW, Van Hove JLK, Hittel D, and Khan A (2020) Improved lactate control with dichloroacetate in a case with severe neonatal lactic acidosis due to MTFMT mitochondrial translation disorder, in: *Mol Genet Metab Rep*, pp 100616, © 2020 Published by Elsevier Inc.
- Berendzen K, Theriaque DW, Shuster J, and Stacpoole PW (2006) Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. *Mitochondrion* 6:126-135.
- Bersin RM and Stacpoole PW (1997) Dichloroacetate as metabolic therapy for myocardial ischemia and failure. *Am Heart J* 134:841-855.
- Brue T, Amodru V, and Castinetti F (2018) MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushing's syndrome during pregnancy: solved and unsolved questions. *Eur J Endocrinol* 178:R259-r266.
- Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, and Ambrose PG (2013) Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. *Antimicrobial agents and chemotherapy* 57:498-507.
- Cornett R, James MO, Henderson GN, Cheung J, Shroads AL, and Stacpoole PW (1999) Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity. *Biochem Biophys Res Commun* 262:752-756.
- Dimmer KS, Friedrich B, Lang F, Deitmer JW, and Bröer S (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. *Biochemical Journal* 350:219-227.
- Donohue JM, Galal-Gorchev H, Brattin W, Liccione. JJ, and . KBA (2003) TOXICOLOGICAL REVIEW OF DICHLOROACETIC ACID (CAS No. 79-43-6)

- In Support of Summary Information on the Integrated Risk Information System (IRIS) (Agency USEP ed, , Washington, DC.
- Eguiluz A, López Bernal A, McPherson K, Parrilla JJ, and Abad L (1983) The use of intrapartum fetal blood lactate measurements for the early diagnosis of fetal distress. *Am J Obstet Gynecol* 147:949-954.
- Eriksson BO, Holmgren D, Wåhlander H, Oldfors A, Holme E, and Tulinius M (2003) Cardiomyopathy in children with mitochondrial disease: Clinical course and cardiological findings. *European Heart Journal* 24:280-288.
- Fatica EM, DeLeonibus GA, House A, Kodger JV, Pearce RW, Shah RR, Levi L, and Sandlers Y (2019) Barth Syndrome: Exploring Cardiac Metabolism with Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *Metabolites* 9.
- Jahn SC, Smeltz MG, Hu Z, Rowland-Faux L, Zhong G, Lorenzo RJ, Cisneros KV, Stacpoole PW, and James MO (2018) Regulation of dichloroacetate biotransformation in rat liver and extrahepatic tissues by GSTZ1 expression and chloride concentration. *Biochem Pharmacol* 152:236-243.
- James MO, Jahn SC, Zhong G, Smeltz MG, Hu Z, and Stacpoole PW (2017) Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. *Pharmacology & therapeutics* 170:166-180.
- Jensen E, Wood C, and Keller-Wood M (2002) The normal increase in adrenal secretion during pregnancy contributes to maternal volume expansion and fetal homeostasis. *J Soc Gynecol Investig* 9:362-371.
- Joseph S, Alava B, Antolic A, Richards EM, Wood CE, and Keller-Wood M (2020) Fetal ovine skeletal and cardiac muscle transcriptomics are differentially altered by increased maternal cortisol during gestation. *Physiol Genomics* 52:178-190.
- Kajimoto M, Nuri M, Isern NG, Robillard-Frayne I, Des Rosiers C, and Portman MA (2019) Metabolic Response to Stress by the Immature Right Ventricle Exposed to Chronic Pressure Overload. *J Am Heart Assoc* 8:e013169.
- Keller-Wood M, Feng X, Wood CE, Richards E, Anthony RV, Dahl GE, and Tao S (2014) Elevated maternal cortisol leads to relative maternal hyperglycemia and increased stillbirth in ovine pregnancy. *American Journal of Physiology - Regulatory, Integrative and Comparative Physiology* 307:R405-R413.
- Langae T, Wagner R, Horne LP, Lawson LA, Becker C, Shahin M, Starostik P, and Stacpoole PW (2018) Personalized Dosing of Dichloroacetate Using GSTZ1 Clinical Genotyping Assay. *Genet Test Mol Biomarkers* 22:266-269.
- Li W, Gu Y, James MO, Hines RN, Simpson P, Langae T, and Stacpoole PW (2012) Prenatal and postnatal expression of glutathione transferase ζ 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate. *Drug metabolism and disposition: the biological fate of chemicals* 40:232-239.
- László KD, Svensson T, Li J, Obel C, Vestergaard M, Olsen J, and Cnattingius S (2013) Maternal bereavement during pregnancy and the risk of stillbirth: a nationwide cohort study in Sweden. *Am J Epidemiol* 177:219-227.
- Magida JA and Leinwand LA (2014) Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy. *EMBO Mol Med* 6:482-495.
- McCall CE, Zabalawi M, Liu T, Martin A, Long DL, Buechler NL, Arts RJW, Netea M, Yoza BK, Stacpoole PW, and Vachharajani V (2018) Pyruvate dehydrogenase

- complex stimulation promotes immunometabolic homeostasis and sepsis survival. *JCI Insight* 3.
- Michelakis ED, Gurtu V, Webster L, Barnes G, Watson G, Howard L, Cupitt J, Paterson I, Thompson RB, Chow K, O'Regan DP, Zhao L, Wharton J, Kiely DG, Kinnaird A, Boukouris AE, White C, Nagendran J, Freed DH, Wort SJ, Gibbs JSR, and Wilkins MR (2017) Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. *Science Translational Medicine* 9:eaao4583.
- Morrison JL, Berry MJ, Botting KJ, Darby JRT, Frasch MG, Gattford KL, Giussani DA, Gray CL, Harding R, Herrera EA, Kemp MW, Lock MC, McMillen IC, Moss TJ, Musk GC, Oliver MH, Regnault TRH, Roberts CT, Soo JY, and Tellam RL (2018) Improving pregnancy outcomes in humans through studies in sheep. *Am J Physiol Regul Integr Comp Physiol* 315:R1123-r1153.
- Pilegaard H and Neufer PD (2004) Transcriptional regulation of pyruvate dehydrogenase kinase 4 in skeletal muscle during and after exercise. *Proc Nutr Soc* 63:221-226.
- Richards EM, Wood CE, Rabaglino MB, Antolic A, and Keller-Wood M (2014) Mechanisms for the adverse effects of late gestational increases in maternal cortisol on the heart revealed by transcriptomic analyses of the fetal septum. *Physiological Genomics* 46:547.
- Shinozuka N, Yen A, and Nathanielsz PW (1999) Alteration of fetal oxygenation and responses to acute hypoxemia by increased myometrial contracture frequency produced by pulse administration of oxytocin to the pregnant ewe from 96 to 131 days' gestation. *Am J Obstet Gynecol* 180:1202-1208.
- Shroads AL, Coats BS, McDonough CW, Langaee T, and Stacpoole PW (2015) Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children. *J Clin Pharmacol* 55:50-55.
- Shroads AL, Guo X, Dixit V, Liu HP, James MO, and Stacpoole PW (2008) Age-dependent kinetics and metabolism of dichloroacetate: possible relevance to toxicity. *J Pharmacol Exp Ther* 324:1163-1171.
- Shroads AL, Henderson GN, Cheung J, James MO, and Stacpoole PW (2004) Unified gas chromatographic-mass spectrometric method for quantitating tyrosine metabolites in urine and plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 808:153-161.
- Shroads AL, Langaee T, Coats BS, Kurtz TL, Bullock JR, Weithorn D, Gong Y, Wagner DA, Ostrov DA, Johnson JA, and Stacpoole PW (2012) Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. *J Clin Pharmacol* 52:837-849.
- Silver RM and Ruiz RJ (2013) Invited Commentary: Maternal Stress and Stillbirth—Another Piece of the Puzzle. *American Journal of Epidemiology* 177:228-229.
- Smeltz MG, Hu Z, Zhong G, Jahn SC, Rowland-Faux L, Horne LP, Stacpoole PW, and James MO (2019) Mitochondrial Glutathione Transferase Zeta 1 Is Inactivated More Rapidly by Dichloroacetate than the Cytosolic Enzyme in Adult and Juvenile Rat Liver. *Chem Res Toxicol* 32:2042-2052.
- Smith MK, Randall JL, Read EJ, and Stober JA (1992) Developmental toxicity of dichloroacetate in the rat. *Teratology* 46:217-223.

- Smith NC, Soutter WP, Sharp F, McColl J, and Ford I (1983) Fetal scalp blood lactate as an indicator of intrapartum hypoxia. *Br J Obstet Gynaecol* 90:821-831.
- Squirewell EJ, Smeltz MG, Rowland-Faux L, Horne LP, Stacpoole PW, and James MO (2020) Effects of Multiple Doses of Dichloroacetate on GSTZ1 Expression and Activity in Liver and Extrahepatic Tissues of Young and Adult Rats. *Drug metabolism and disposition: the biological fate of chemicals* 48:1217-1223.
- Stacpoole PW (1993) Lactic acidosis. *Endocrinol Metab Clin North Am* 22:221-245.
- Stacpoole PW (2011) The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither? *Environ Health Perspect* 119:155-158.
- Stacpoole PW (2017) Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer. *J Natl Cancer Inst* 109.
- Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW, and Shuster JJ (2008) Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. *Pediatrics* 121:e1223-1228.
- Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, and Misbin RI (1983) Treatment of lactic acidosis with dichloroacetate. *N Engl J Med* 309:390-396.
- Stacpoole PW, Martyniuk CJ, James MO, and Calcutt NA (2019) Dichloroacetate-induced peripheral neuropathy. *Int Rev Neurobiol* 145:211-238.
- Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, Duncan CA, Harman EM, Henderson GN, Jenkinson S, and et al. (1992) A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. *N Engl J Med* 327:1564-1569.
- Subramani K, Lu S, Warren M, Chu X, Toque HA, Caldwell RW, Diamond MP, and Raju R (2017) Mitochondrial targeting by dichloroacetate improves outcome following hemorrhagic shock. *Scientific reports* 7:2671-2671.
- Sugden MC and Holness MJ (2003) Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. *American Journal of Physiology-Endocrinology and Metabolism* 284:E855-E862.
- Sun Y, Li T, Xie C, Zhang Y, Zhou K, Wang X, Blomgren K, and Zhu C (2016) Dichloroacetate treatment improves mitochondrial metabolism and reduces brain injury in neonatal mice. *Oncotarget* 7:31708-31722.
- Tzeng HF, Blackburn AC, Board PG, and Anders MW (2000) Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. *Chem Res Toxicol* 13:231-236.
- Vannuccini S, Bocchi C, Severi FM, and Petraglia F (2016) Diagnosis of Fetal Distress, in: *Neonatology: A Practical Approach to Neonatal Diseases* (Buonocore G, Bracci R, and Weindling M eds), pp 1-23, Springer International Publishing, Cham.
- Walejko JM, Antolic A, Koelmel JP, Garrett TJ, Edison AS, and Keller-Wood M (2019) Chronic maternal cortisol excess during late gestation leads to metabolic alterations in the newborn heart. *Am J Physiol Endocrinol Metab* 316:E546-e556.
- Yan Z, Henderson GN, James MO, and Stacpoole PW (1997) Determination of dichloroacetate and its metabolites in human plasma by gas chromatography-mass spectrometry. *J Chromatogr B Biomed Sci Appl* 703:75-84.

Zhong G, James MO, Smeltz MG, Jahn SC, Langaee T, Simpson P, and Stacpoole PW (2018) Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1. *Drug Metabolism and Disposition* 46:1118.

Footnotes

This work was supported by the **National Institutes of Health**, National Institute of Child Health and Development [Grant **R21** HD091599].

The authors have no financial disclosures to make.

Portions of this work were included in Serene Joseph's Ph.D. Dissertation, "Effects of maternal hypercortisolemia on fetal and neonatal metabolism in heart and diaphragm," located at the University of Florida Digital Collections. Preliminary report of some portions of this work was presented in April 2019 at the National Meeting of Experimental Biology.

Figure Captions

Figure 1: Mean concentration-time profile of DCA in fetus and mother in Study I (upper panel) after maternal intravenous bolus doses of DCA (25 mg/kg every 12h) in pregnant ewes or in Study II (lower panel) after maternal bolus and infusion of DCA (25 mg/kg at 0h, followed by an infusion of 12.5mg DCA/kg/h for 8 h, and an infusion of 6.25 mg DCA/kg/h from 8-24h). Closed circles indicate maternal values and open circles indicate fetal values. Error bar represents standard error of the mean (SEM)

Figure 2: Pharmacokinetic model for mother and fetus receiving 25 mg/kg over 5 doses in 3 days using a multicompartmental model). A1, A2 and A3 are described as maternal, placental, and fetal compartments, respectively. Micro constants, K_{12} , K_{21} , K_{23} , and K_{32} are intercompartmental distribution rate constants. Autoinhibition (INH_M and INH_F) of clearances of both ewes (CL) and fetuses (CL_F) were described using K_p (turnover rate constant for inhibition), I_{max} (maximum inhibition), and IC_{50} (concentration causing 50% of I_{max})

Figure 3: Observed plasma concentrations versus individual prediction by final model of DCA.(DV dependent (observed) concentration; IPRED, individual predicted concentration) for data from Study I (upper panels; $r^2=0.95$ in ewe, left and 0.94 in fetus, right) and Study II (lower panels; $r^2=0.41$ in ewe, left and 0.93 in fetus, right)

Figure 4: DCA administration reduced the relative expression of GSTZ1 in fetal and maternal liver cytosol. Individual data points, mean and S.D. are shown for each group. Different letters, A, B, C indicate groups with significantly different expression (n=4-8 per group)

Figure 5: Maternal (A-B) and Fetal (C-D) concentrations of glucose (A,C) and lactate (B,D) after the first dose (Day 1, circles) or fifth dose (Day 3, squares) in Study I (n=4)

Figure 6: Maternal (A-B) and Fetal (C-D) concentrations of glucose (A,C) and lactate (B,D) during maternal DCA treatment in Study II (n=8)

Table 1. Estimated pharmacokinetic parameters for DCA derived from multi-compartmental pharmacokinetic analysis

Parameter	Units	Estimate (%CV)	95% CI
Volume of central compartment (V)	L	63.3 (10.8)	54.4- 72.7
Clearance without inhibition (CL)	L/h	195.7 (12.2)	158.9-220.1
Distribution rate constant from central to Placental compartment (K_{12})	1/h	0.18 (22.3)	0.16-0.27
Distribution rate constant from placental to central compartment (K_{21})	1/h	0.16 (21.6)	0.15-0.17
Distribution rate constant from placental to fetal compartment (K_{23})	1/h	3.08 (35.1)	2.7-5.8
Distribution rate constant from fetal to placental compartment K_{32}	1/h	2.2 (20.3)	2.0-3.3
Clearance in fetus without inhibition (CL_F)	L/h	122.4 (28.2)	105.3-196.4
Fetal volume of distribution (V_2)	L	51.6 (12.2)	48.9-65.7
Concentration for 50% inhibition (IC_{50})	mg/L	0.04 (11.2)	0.03-0.05
Maximum inhibition (I_{max})		0.74 (5.2)	0.74-0.86
Turnover rate constant of inhibition (K_p)		1.29 (5.4)	1.13-1.29




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6

Supplemental Material for manuscript: DMD-AR-2020-000330


Title: Pharmacokinetic and biochemical profiling of Sodium Dichloroacetate in pregnant ewes and fetuses

Authors: Joseph S, Sharma A, Horne LP, Wood CE, Langaee T, James MO, Stacpoole PW, and Keller-Wood M


Journal: Drug Metabolism and Disposition



Supplemental Figure 1: Visual predictive checks (VPC) of the final model for DCA in mother and fetus



Supplemental Figure 2: Observed concentrations and individual predictions versus time (CObs, mother and CObs2, fetus) using data in Study I



1. Mol wt markers (31 and 21.5 kDaltons)
2. Maternal control, 80 μ g protein
3. Maternal control, 80 μ g protein
4. Maternal control, 80 μ g protein
5. Maternal control, 80 μ g protein
6. Fetal control, 80 μ g protein
7. Fetal control, 80 μ g protein
8. Rat liver cytosol, 5 μ g protein

Supplemental Figure 3: Representative figure showing GSTZ1 bands from maternal and fetal mitochondrial samples.

Supporting Table 1. Primer sequences used in PCR and sequencing of the ovine GSTZ1 gene

EXON	primer	Sequence	GC%	Tm	Extension and Annealing conditions
1	FP	ACCCGAGACCTTGGGGCGCA	70	69.3	95°- 30s, 62°-30s (40 cycles), 72°(1min)
	RP	GCGCCTCAGTGTTTCTAAGCAGC	56.5	63.2	
2	FP	TTCAGCAGTTGCTCCCTCTT	50	60.13	95°- 30s, 58°-45s (50 cycles), 72°(1min)
	RP	GCTCTTTGTGTGGTTCAGCA	50	60.13	
3	FP	GACCCCAAGGCCTCTATC	55.1	59.32	95°- 30s, 56 °-30s (40 cycles), 72°(1min)
	RP	CCAAGGTGGACATGTCTTCA	55	59.59	
4	FP	TGGCGCAGAGAAAGAAGATT	45	60.1	95°- 30s, 58°-45s (50 cycles), 72°(1min)
	RP	TGTCCCATGAGGGAGAGC	61.1	59.7	
5	FP	TTCCTGCTTGCTCCTTTCTG	50	60.65	95°- 30s, 58°-45s (50 cycles), 72°(1min)
	RP	CTCCTCACTTCCCAAAGCAA	50	60.37	
6	FP	GTGTTGGAAGTGGAGGAGGA	55	60.09	95°- 30s, 58°-45s (50 cycles), 72°(1min)
	RP	CTGGGGGATGGGTATTTTCT	50	60.01	
7	FP	GGTCCAGGGTAGGACAGGTG	65	61.75	95°- 30s, 58°-45s (50 cycles), 72°(1min)
	RP	GACCACTGTCAAGGCCAAAG	55	60.69	
8	FP	ATTCCCTCCAGCACACACTC	55	60.12	95°- 30s, 60°-30s (45 cycles), 72°(1min)
	RP	CACCACAGCTGCCTCCTC	66.7	60.58	
9	FP	GCTACCCACAGAGCTGGTT	60	60.85	95°- 30s, 58°-45s (50 cycles), 72°(1min)
	RP	AGGAGGAAGCTGGGTGTTTT	50	60.11	

10	FP	GCAGGGCCACCTTCCTAC	66.7	60.62	95° - 30s, 62°-30s (50 cycles), 72°(45s)
	RP	GCTCACTTCTAGGCAAGTTCAG	50	58.42	
